The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Inflammation and Schizophrenia
Open accessAbstract
An association between inflammatory abnormalities and schizophrenia has been found repeatedly. The purposes of this special feature are to clarify the key findings on inflammation in schizophrenia, identify major gaps in the literature, and suggest priorities for research in this area. Inflammation is one of the body’s first lines of defense in response to injury or infection, and increased inflammation is found in many diseases. Acute inflammation is a nonspecific response characterized by warmth, pain, and swelling. Leukocytes migrate to the area of injury and become activated, the blood supply to the area increases, and blood vessels become more permeable, allowing cells and molecules to leave blood vessels and enter the injured tissue. The inflammatory response also involves the complement system, a group of proteins that, when activated, combine to form a complex molecular structure that kills cells, usually bacteria and parasites. Cytokines are key molecules that regulate inflammation; they also have important roles in the immune system. They are produced by a wide variety of immune cells and cells outside of the immune system. The term cytokine derives from their ability to influence the movement of inflammatory cells, but they also have other functions. Chronic inflammation is usually a lower grade response, lacks the grossly visible signs of acute inflammation, and may be systemic rather than localized. Chronic inflammation plays a role in the pathophysiology of many chronic diseases, including cardiovascular and cerebrovascular disease, diabetes, Alzheimer’s disease, and some cancers. The characteristics of chronic inflammation differ somewhat in the brain from what occurs in other tissues. An important component of neuroinflammation is the microglial activation. The brain contains relatively few of the inflammatory cells that are found outside the brain. Microglia, which are related to the peripheral inflammatory cells, serve some of the protective functions such cells play in the rest of the body. Microglia are involved in other brain functions, including the pruning and maintenance of synapses, trafficking of neurotransmitters, and devouring—phagocytosis—of cell fragments and damaged cells. Activated microglia produce inflammatory cytokines and the phagocytose cells or proteins that provoke the inflammatory response. Microglial activation and subsequent proinflammatory cytokine production may disrupt the blood-brain barrier (BBB). An intact BBB usually tightly controls the entry of cytokines and leukocytes into brain tissue. Damage to the BBB impairs its ability to control which inflammatory cells and molecules enter the brain; other substances leak into brain tissue, and the brain is unable to function normally. A discussion of prenatal inflammation as a risk factor for schizophrenia is beyond the scope of the present special feature, and the reader is referred to previous reviews of human1,2 and animal studies.3–6 Numerous studies have found that people with schizophrenia have increased blood concentrations of inflammatory cytokines.7 Two important themes emerge from these studies. First, inflammatory abnormalities are present in subjects with first-episode, drug-naive psychosis (FEP) compared with controls, suggesting an association that may be independent of the effects of antipsychotic medications. Second, the concentrations of some inflammatory molecules may vary with the clinical status of patients: ie, there appear to be separate groups of state and trait markers. The state-related markers include interleukin (IL) 1-beta, IL-6, and transforming growth factor-beta. People with schizophrenia have higher concentrations of these cytokines than controls during an exacerbation of symptoms, but there is no difference during periods of clinical stability. IL-12, interferon-gamma, and tumor necrosis factor-alpha (TNF-alpha) appear to be trait markers. Concentrations of these cytokines are higher in patients with FEP than in controls, and in patients with chronic illness, during both periods of symptomatic worsening, than in controls. C-reactive protein (CRP), another proinflammatory molecule, also appears to be a state marker,8 and specific lymphocyte populations may also segregate into state and trait markers.9 Additional evidence for potential state-related markers in schizophrenia has been reviewed elsewhere.10 Two studies suggest that inflammatory molecules may predict subsequent relapse.11,12 Other studies have found abnormal levels of inflammatory parameters in the central nervous system (CNS) in schizophrenia, including cerebrospinal fluid (CSF) cytokine11 and leukocyte levels,13,14 CNS microglia and lymphocytes,15–19 CSF and CNS oxidative stress,20,21 and anti-N-methyl-D-aspartate receptor autoantibodies.22 There is also evidence suggesting that infections may be associated with illness relapse.23 Within schizophrenia, blood cytokine abnormalities have been associated with poorer cogniti
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
Self-citationRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Brown, A. S., & Derkits, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030361 · Cited by 1,269
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
Patterson, P. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.016 · Cited by 766
Early-life programming of later-life brain and behavior: a critical role for the immune system
Bilbo, S. D. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.014.2009 · Cited by 652
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways
Maes, M., Berk, M., Goehler, L., Song, C., Anderson, G., Gałecki, P., & Leonard, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-66 · Cited by 629
Boksa, P. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.03.005 · Cited by 603
van Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R. A., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 559
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540
O’Connor, M.-F., Bower, J. E., Cho, H. J., Creswell, J. D., Dimitrov, S., Hamby, M. E., Hoyt, M. A., Martin, J. L., Robles, T. F., Sloan, E. K., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.04.005 · Cited by 500
Meta-analysis of oxidative stress in schizophrenia.
Flatow, J., Buckley, P., & Miller, B. J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.018 · Cited by 491
Self-citationElevated Maternal Interleukin-8 Levels and Risk of Schizophrenia in Adult Offspring
Brown, A. S., Hooton, J., Schaefer, C. A., Zhang, H., Petkova, E., Babulas, V., Perrin, M., Gorman, J. M., & Susser, E. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.889 · Cited by 489
Oxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
Zalcman, S., Green-Johnson, J. M., Murray, L., Nance, D. M., Dyck, D., Anisman, H., & Greenberg, A. H. (1994) · Brain Research · doi:10.1016/0006-8993(94)90006-x · Cited by 439
Immune–neural connections: how the immune system’s response to infectious agents influences behavior
McCusker, R. H., & Kelley, K. W. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.073411 · Cited by 429
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Altered glutathione redox state in schizophrenia.
Yao, J. K., Leonard, S., & Reddy, R. (2006) · Disease Markers · doi:10.1155/2006/248387 · Cited by 321
Maternal Cytokine Levels during Pregnancy and Adult Psychosis
Buka, S. L., Tsuang, M. T., Torrey, E. F., Klebanoff, M. A., Wagner, R. L., & Yolken, R. H. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2001.0644 · Cited by 321
A Review of the Fetal Brain Cytokine Imbalance Hypothesis of Schizophrenia
Meyer, U., Feldon, J., & Yee, B. K. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn022 · Cited by 320
Borrell, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00360-8 · Cited by 307
Mondelli, V., Cattaneo, A., Murri, M. B., Di Forti, M., Handley, R., Hepgul, N., Miorelli, A., Navari, S., Papadopoulos, A. S., Aitchison, K. J., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06745 · Cited by 303
Samuelsson, A.-M., Jennische, E., Hansson, H.-A., & Holmäng, A. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00268.2005 · Cited by 285
C-Reactive Protein Levels in Schizophrenia: A Review and Meta-Analysis
Miller, B. J., Culpepper, N., & Rapaport, M. H. (2014) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.micu.020813 · Cited by 267
Self-citationImpaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
Nilsson, L. K., Linderholm, K. R., Engberg, G., Paulson, L., Blennow, K., Lindström, L. H., Nordin, C., Karanti, A., Persson, P., & Erhardt, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.013 · Cited by 238
Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Gassama, B., Sebastian, D., Buckley, P., & Mellor, A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.007 · Cited by 233
Self-citationDistribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization
Steiner, J., Mawrin, C., Ziegeler, A., Bielau, H., Ullrich, O., Bernstein, H.-G., & Bogerts, B. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0090-8 · Cited by 229
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., & Correll, C. U. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt070 · Cited by 204
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1291 · Cited by 204
Busse, S., Busse, M., Schiltz, K., Bielau, H., Gos, T., Brisch, R., Mawrin, C., Schmitt, A., Jordan, W., Müller, U. J., et al. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.08.005 · Cited by 194
Nawa, H., & Takei, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.06.002 · Cited by 174
Song, C., Merali, Z., & Anisman, H. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00271-1 · Cited by 172
Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly
Sardi, F., Fassina, L., Venturini, L., Inguscio, M., Guerriero, F., Rolfo, E., & Ricevuti, G. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.09.005 · Cited by 172
Romero, E., Guaza, C., Castellano, B., & Borrell, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.44 · Cited by 163
Kim, Y.-K., Kim, L., & Lee, M.-S. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00171-1 · Cited by 158
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources
Anderson, R. E., Hansson, L., Nilsson, O., Liška, J., Settergren, G., & Vaage, J. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(01)02399-2 · Cited by 143
Romero, E., Ali, C., Molina‐Holgado, E., Castellano, B., Guaza, C., & Borrell, J. I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301292 · Cited by 143
Rheumatold Arthritis and Senile Dementia of the Alzhelmer's Type
Jenkinson, M. L., Bliss, M. R., BRAIN, A. T., & Scott, D. L. (1989) · Lara D. Veeken · doi:10.1093/rheumatology/28.1.86-b · Cited by 143
Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies
Miller, B. J., Culpepper, N. H., Rapaport, M. H., & Buckley, P. F. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.03.010 · Cited by 142
Self-citationA systematic, quantitative review of blood autoantibodies in schizophrenia
Ezeoke, A., Mellor, A. L., Buckley, P. F., & Miller, B. J. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.029 · Cited by 131
Self-citationGarcía‐Rizo, C., Fernández-Egea, E., Oliveira, C., Justicia, A., Bernardo, M., & Kirkpatrick, B. W. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.08.014 · Cited by 103
Self-citationAccumulation of Macrophages in the CSF of Schizophrenic Patients During Acute Psychotic Episodes
Nikkil⺯, H. V., M�, K., Ahokas, A., Miettinen, K., Rimón, R., & Andersson, L. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1725 · Cited by 98
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96
Nikkilä, H. V., Müller, K., Ahokas, A., Rimón, R., & Andersson, L. C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00218-2 · Cited by 95
An Association of Autoantibody Status and Serum Cytokine Levels in Type 1 Diabetes
Hanifi-Moghaddam, P., Schloot, N. C., Kappler, S., Seiβler, J., & Kolb, H. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1137 · Cited by 83
Schroeter, M. L., Abdul‐Khaliq, H., Krebs, M., Diefenbacher, A., & Blasig, I. E. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.01.002 · Cited by 78
Kleine, T. O., Benes, L., & Zöfel, P. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00090-x · Cited by 70
Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats
Zalcman, S., Savina, I., & Wise, R. A. (1999) · Brain Research · doi:10.1016/s0006-8993(99)02063-6 · Cited by 69
NEUROBEHAVIORAL AND IMMUNOLOGICAL CONSEQUENCES OF PRENATAL IMMUNE ACTIVATION IN RATS
Borrell, J. I. (2008) · Schizophrenia Research · doi:10.1016/s0920-9964(08)70050-1 · Cited by 66
A Prevalence Study of Urinary Tract Infections in Acute Relapse of Schizophrenia
Miller, B. J., Graham, K. L., Bodenheimer, C. M., Culpepper, N. H., Waller, J. L., & Buckley, P. F. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08050 · Cited by 66
Self-citationPriming of Metabolic Dysfunctions by Prenatal Immune Activation in Mice: Relevance to Schizophrenia
Pacheco‐López, G., Giovanoli, S., Langhans, W., & Meyer, U. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr178 · Cited by 66
Hirota, T., & Kishi, T. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.038 · Cited by 64
Membrane Phospholipids and Cytokine Interaction in Schizophrenia
Yao, J. K., & van Kammen, D. P. (2004) · International review of neurobiology · doi:10.1016/s0074-7742(04)59012-8 · Cited by 62
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Ravikumar, A., Deepadevi, K. V., Arun, P., Manojkumar, V., & Kurup, P. A. (2000) · PubMed · Cited by 59
Prasad, K. M. R., Eack, S. M., Keshavan, M. S., Yolken, R. H., Iyengar, S., & Nimgaonkar, V. L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs040 · Cited by 59
Macrophages make me sick: How macrophage activation states influence sickness behavior
Moon, M. L., McNeil, L. K., & Freund, G. G. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.002 · Cited by 52
Nunes, S. O. V., Matsuo, T., Kaminami, M. S., Watanabe, M. A. E., Reiche, E. M. V., & Itano, E. N. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.003 · Cited by 50
Altered immune function in unaffected first-degree biological relatives of schizophrenia patients
Martínez‐Gras, I., García-Sánchez, F., Guaza, C., Rodríguez–Jiménez, R., Andres, E. M., Palomo, T., Rubio, G., & Borrell, J. I. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.05.036 · Cited by 46
Zhang, X. Y., Cao, L. Y., Song, C., Wu, G. Y., Chen, D. C., Qi, L. Y., Wang, F., Xiu, M. H., Chen, S., Zhang, Y., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1295-4 · Cited by 43
Markers of inflammation in the prefrontal cortex of individuals with schizophrenia
Fillman, S. G., Cloonan, N., Miller, L. C., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.199 · Cited by 41
Soluble interleukin 2 receptor levels in families of people with schizophrenia
Gaughran, F., O'Neill, E., Sham, P. C., Daly, R. J., & Shanahan, F. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00275-4 · Cited by 30
Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia
Liu, H., Kang, Y., Liang, J., Li, C., Xiu, M., Chen, D., Yang, F., Wang, F., Wu, G., Haile, C. N., et al. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.01.002 · Cited by 28
Karl Jaspers and the Genesis of Delusions in Schizophrenia
Maj, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs190 · Cited by 25
Clinical and Immunological Characteristics of a Subgroup of Patients Suffering from Schizophrenia
Ganguli, R., & Gubbi, A. V. (1997) · KARGER eBooks · doi:10.1159/000058633 · Cited by 13
Is Relapse in Schizophrenia an Immune-Mediated Effect?
Miller, B. J., & Buckley, P. F. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.2.115 · Cited by 9
Self-citation
Cited by
The kynurenine pathway: a finger in every pie
Savitz, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 756
Molecular and functional neuroscience in immunity
Pavlov, V. A., Chavan, S. S., & Tracey, K. J. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053158 · Cited by 444
Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications
Rajasekaran, A., Venkatasubramanian, G., Berk, M., & Debnath, M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.005 · Cited by 279
Kim, Y.-K., & Shin, C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170915141036 · Cited by 271
Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis
Fraguas, D., Díaz-Caneja, C. M., Ayora, M., Hernández-Álvarez, F., Rodríguez-Quiroga, A., Recio, S., Leza, J. C., & Arango, C. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby125 · Cited by 270
Metadata
- Authors
- Kirkpatrick, B., & Miller, B. J.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-26
- Volume
- 39
- Issue
- 6
- Pages
- 1174-1179
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2130148029
- Cited by
- 312
- References
- 72
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.